Digital health companies, investors, and other healthcare organizations should follow policy developments with a strategic lens towards their market opportunities for key potential growth and risk mitigation. On April 29, 2024, after more than a decade of debate, Congressional activity, and proposed regulatory action, the Food and Drug Administration (FDA) finalized a rule asserting its authority to regulate laboratory developed tests (LDTs) as medical devices ("Final Rule").